Squarepoint Ops LLC Purchases Shares of 475,571 Roivant Sciences Ltd. $ROIV

Squarepoint Ops LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 475,571 shares of the company’s stock, valued at approximately $16,830,000.

A number of other large investors also recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. lifted its holdings in Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after buying an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after purchasing an additional 34,341 shares in the last quarter. American Century Companies Inc. raised its position in Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after purchasing an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after buying an additional 6,879 shares during the period. Finally, M&T Bank Corp grew its position in shares of Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 0.8%

NASDAQ:ROIV opened at $41.81 on Thursday. Roivant Sciences Ltd. has a 12-month low of $13.40 and a 12-month high of $42.50. The stock’s 50 day simple moving average is $35.56 and its 200-day simple moving average is $31.46. The firm has a market cap of $30.20 billion, a P/E ratio of -78.89 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. Research analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $35.77, for a total value of $7,154,000.00. Following the sale, the chief executive officer owned 1,599,154 shares of the company’s stock, valued at approximately $57,201,738.58. The trade was a 11.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Gold sold 12,380 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total value of $436,766.40. Following the transaction, the director owned 13,689,166 shares in the company, valued at $482,953,776.48. The trade was a 0.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055,913 shares of company stock worth $107,261,258 over the last quarter. 8.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of analyst reports. UBS Group set a $55.00 price objective on shares of Roivant Sciences in a report on Wednesday. Guggenheim boosted their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday. Citigroup increased their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, HC Wainwright increased their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.62.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant unit reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance, supporting the drug’s potential in a serious disease with substantial unmet need. Roivant PHocus study announcement
• Positive Sentiment: Roivant has started the Phase 3 PHrontier trial, advancing mosliciguat toward a potential registration-enabling study. The transition to late-stage development reduces some development uncertainty and increases the potential value of the program. Mosliciguat Phase 3 trial report
• Positive Sentiment: Analysts raised their price targets while maintaining buy ratings: Jefferies increased its target to $52 from $42, and HC Wainwright raised its target to $47 from $41. These revisions indicate increased confidence in Roivant’s pipeline and commercial prospects.
• Positive Sentiment: Unusually heavy call-option activity and reports that hedge-fund holdings rose 41% added to bullish trading momentum, although options activity is a market-positioning signal rather than a fundamental change. Roivant hedge fund holdings report
• Positive Sentiment: Roivant and partner Priovant are also commercializing Lisraya, described as the first oral FDA-approved treatment for dermatomyositis, with a reported list price of $35,000 per 30-day supply. The launch creates another potential revenue stream, though uptake and reimbursement remain important uncertainties.
• Neutral Sentiment: Management presented at the Wells Fargo and Cantor Fitzgerald healthcare conferences, giving investors additional updates on the pipeline and strategy. The available reports do not identify a separate material announcement from those presentations. Cantor Fitzgerald conference transcript

Roivant Sciences Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.